01 January 2002
Drug-induced liver damage - a three-year study of patients from one gastroenterological department.
Lukasz Biernat, Marek Hartleb, Anna KochelMed Sci Monit 2002; 8(4): CR292-296 :: ID: 420865
Abstract
BACKGROUND: The aim of our study was to analyze drug-induced liver diseaseover a 3-year period in one gastroenterological department. MATERIAL/METHODS: International consensusstandard definitions and criteria for assessing causality of adverse drug reactions were applied to allpatients with abnormal hepatic test results. RESULTS: Drugs were implicated in hepatic injury in 14 patients(8 females) in whom causal relationship between drug and liver disease was definite or highly probable.The drugs responsible were amoxicillin with clavulanic acid (3 cases), fluvastatin and pravastatin (3cases), antituberculous drugs (2 cases), estrogens, roxithromycin, asacol, satolol, enalapril and thiamazol.A total of 78.6% (11 cases) were classified as hepatocellular or mixed hepatitis, while cholestatic injurywas found in 21.4% (3 cases). There were no lethal or severe (prothrombin < 50%) hepatic drug reactions.In 13 patients the course of liver disease after withdrawal of the offensive drug was either acute orprotracted, while in one patient there was chronic cholestasis (>3 years) resulting from injury to interlobularbile ducts by amoxicllin with clavulanic acid. CONCLUSIONS: A thorough history of drug intake shouldbe taken in all patients presenting with abnormal hepatic test results. Amoxicillin & clavulanic acid,cholesterol-lowering and antituberculin drugs were the most frequent hepatotoxic factors in our patients.In a majority of cases the liver injury was not severe, and resolved after prompt withdrawal of the responsibledrug.
Keywords: Anti-Bacterial Agents, Anti-Inflammatory Agents, Non-Steroidal, Anticholesteremic Agents, Antitubercular Agents, Comorbidity, enalapril, Estrogens, Fatty Liver, Hepatitis, Toxic, Liver Diseases, Mesalamine
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952